Inhibiteurs allostériques de la protéase ns3 du virus de l'hépatite c virus

Allosteric inhibitors of ns3 protease from hepatitis c virus

Abstract

The present invention provides compounds for use in a method for treatment of hepatitis C, wherein the compound binds to the inactive conformational state of the Zn+2-free NS3 protease of the hepatitis C virus (HCV), stabilizing said conformation, and therefore preventing the activating effect of the interaction with the two cofactors, Zn+2 and NS4A, and, thus, effectively inhibiting allosterically the catalytic activity of the protease.
La présente invention concerne des composés destinés à être utilisés dans un procédé de traitement de l'hépatite C, le composé se liant à l'état conformationnel inactif de la protéase NS3 exempte de Zn+2 du virus de l'hépatite C (VHC), stabilisant ladite conformation et empêchant donc l'effet d'activation de l'interaction avec les deux cofacteurs, Zn+2 et NS4A, et inhibant ainsi de façon efficace de façon allostérique l'activité catalytique de la protéase.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (5)

    Publication numberPublication dateAssigneeTitle
    US-2007213321-A1September 13, 2007Hydra Biosciences, Inc.Compounds for modulating TRPV3 function
    WO-0032177-A2June 08, 2000Hollis-Eden Pharmaceuticals, Inc., Colthurst LtdUse of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections
    WO-2006122156-A2November 16, 2006Hydra Biosciences, Inc.Compounds for modulating trpv3 function
    WO-2010020676-A1February 25, 2010Vib Vzw, Universiteit GentUtilisation d’inhibiteurs de la topoisomérase de type i pour traiter des infections virales
    WO-2010101649-A2September 10, 2010Pablo Gastaminza, Francis ChisariInhibition du récepteur sigma 1 en tant que nouvelle approche thérapeutique contre une infection par le virus de l'hépatite c

NO-Patent Citations (5)

    Title
    A. URBANI: "The Metal Binding Site of the Hepatitis C Virus NS3 Protease. A SPECTROSCOPIC INVESTIGATION", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 30, 24 July 1998 (1998-07-24), pages 18760 - 18769, XP055076030, ISSN: 0021-9258, DOI: 10.1074/jbc.273.30.18760
    DE FRANCESCO ET AL: "Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, vol. 59, no. 12, 10 October 2007 (2007-10-10), pages 1242 - 1262, XP022328021, ISSN: 0169-409X, DOI: 10.1016/J.ADDR.2007.04.016
    F. ROOHVAND ET AL: "Initiation of Hepatitis C Virus Infection Requires the Dynamic Microtubule Network: ROLE OF THE VIRAL NUCLEOCAPSID PROTEIN", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 20, 15 May 2009 (2009-05-15), pages 13778 - 13791, XP055076195, ISSN: 0021-9258, DOI: 10.1074/jbc.M807873200
    OLGA ABIAN ET AL: "Conformational Stability of Hepatitis C Virus NS3 Protease", BIOPHYSICAL JOURNAL, vol. 99, no. 11, 1 December 2010 (2010-12-01), pages 3811 - 3820, XP055076078, ISSN: 0006-3495, DOI: 10.1016/j.bpj.2010.10.037
    OLGA ABIAN ET AL: "Thermodynamics of zinc binding to hepatitis C virus NS3 protease: A folding by binding event", PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, vol. 77, no. 3, 15 November 2009 (2009-11-15), pages 624 - 636, XP055075941, ISSN: 0887-3585, DOI: 10.1002/prot.22475

Cited By (2)

    Publication numberPublication dateAssigneeTitle
    KR-101771784-B1August 28, 2017중앙대학교 산학협력단A pharmaceutical composition for treating and preventing disease in connection with TLR2 signaling
    WO-2015035072-A1March 12, 2015The Arizona Board Of Regents On Behalf Of The University Of ArizonaTraitement et/ou prévention de métastases osseuses